Transglutaminase

 

Celiac disease is a chronic condition in which gluten ingestion triggers damage to the small intestinal mucosa in genetically predisposed individuals. Tissue transglutaminase 2 (tTG) plays a key role in the pathogenesis of the disease.

IgA autoantibodies to tTG are one of the primary serological markers of celiac disease and are used for both for initial laboratory screening and for monitoring treatment effectiveness. Determination of anti-tTG IgG is particularly important in patients with total IgA deficiency. Vitrotest ELISA test kits for the quantitative determination of specific IgA and IgG antibodies provide additional laboratory information for a comprehensive assessment of the patient’s condition.

Go to Top